# OnCo record paper-keynote-062-shitara-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-062-shitara-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-062-shitara-jama-oncol-2020" ;
  schema:name "KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer"@en ;
  schema:description "In first-line PD-L1-positive gastric cancer, pembrolizumab alone was no worse than chemotherapy for survival but did not beat it, and adding it to chemotherapy did not help either; the exception was microsatellite-unstable tumours, which did dramatically better with pembrolizumab."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-062-shitara-jama-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2020.3370>, <https://pubmed.ncbi.nlm.nih.gov/32880601/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2020.3370> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Shitara K, Van Cutsem E, Bang YJ, et al." ;
  onco:cancers <https://onco.cc/cancers/gastric-msi-high/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-062/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .